SCALPEL (Sars-Cov-2 Antibody response in oLder PEopLe) [COVID-19]

• Research type

  Research Study

• Full title

  The antibody (receptor binding (RBD) and nucleocapsid (NP) protein) response in a cohort of older people pre and post vaccination with the Pfizer-BioNTech vaccine to SARS-CoV-2

• IRAS ID

  296291

• Contact name

  Luke Moore

• Contact email

  luke.moore@nhs.net

• Sponsor organisation

  Chelsea and Westminster NHS Foundation Trust

• Duration of Study in the UK

  0 years, 6 months, 2 days

• Research summary

  The primary aim of the study is to characterise the antibody (anti-nucleocapsid, anti-RBD) response to the Pfizer mRNA vaccine to SARS-CoV-2 in residents of the Royal Hospital Chelsea (RHC).
  This will provide greater information about the immunological response to SARS-CoV-2 vaccination in a cohort which represents the highest risk age group for COVID-19 attributed mortality and morbidity.
  In addition we will examine a sub-cohort of participants who have prior serological evidence of exposure to SARS-CoV-2 and assess the temporal RBD/NP antibody response.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  21/EE/0083

• Date of REC Opinion

  15 Mar 2021

• REC opinion

  Favourable Opinion